Several families of protein kinases orchestrate the complex events that drive the cell cycle,
and their activity is frequently deregulated in hyperproliferative cancer cells. Although …

The medical and pharmaceutical communities are facing a dire need for new druggable
targets, while, paradoxically, the targets of some drugs that are in clinical use or …

The specificities of 65 compounds reported to be relatively specific inhibitors of protein
kinases have been profiled against a panel of 70–80 protein kinases. On the basis of this …

Protein kinases are pivotal regulators of cell signaling that modulate each other's functions
and activities through site-specific phosphorylation events. These key regulatory …

Aurora kinase belongs to serine/threonine kinase family which controls cell division.
Therapeutic inhibition of Aurora kinase showed great promise as probable anticancer …

Standard therapeutic approaches of cytotoxics and radiation in cancer are not only highly
toxic, but also of limited efficacy in treatment of a significant number of cancer patients. The …

Preclinical stages in the drug discovery process require a multitude of biochemical and
genetic assays in order to characterize the effects of drug candidates on cellular systems …

Protein kinase inhibitors are a well-established class of clinically useful drugs, particularly
for the treatment of cancer. Achieving inhibitor selectivity for particular protein kinases often …

Over the past four years, the field of the innate immune response has been highly influenced
by the discovery of the IκB kinase (IKK)-related kinases, TANK Binding Kinase 1 (TBK1) and …

TANK-binding kinase 1 (TBK1) plays pivotal roles in antiviral innate immunity. TBK1
mediates the activation of interferon regulatory factor (IRF) 3, leading to the induction of type …